Iron Deficiency Anemia - Intravenous Iron Selection and Dosing

Key Points

• IV iron is indicated when oral iron is ineffective, not tolerated, inadequately absorbed, or too slow for the clinical need.
• Large-dose formulations can replace iron in one or two visits, while iron sucrose usually requires multiple infusions.
• Exact dose and infusion rate are product-specific.
• Severe anaphylaxis is rare with modern IV iron, but infusion reactions require careful assessment.
• Ferric carboxymaltose can cause clinically important hypophosphatemia.
• Red-cell transfusion and IV iron are not interchangeable therapies.
• Do not interpret ferritin without considering inflammation.
• Always identify and treat the cause of iron deficiency.

Algorithm

1. Confirm iron deficiency using ferritin, transferrin saturation, CBC indices, and clinical context.
2. Identify ongoing bleeding, malabsorption, pregnancy, CKD, or other cause.
3. Decide whether oral iron is adequate or IV repletion is preferred.
4. Estimate total iron requirement and choose a formulation that fits dose and visit needs.
5. Administer according to product labeling with observation for infusion reaction.
6. Check phosphate when using repeated ferric carboxymaltose or when risk factors or symptoms are present.
7. Reassess hemoglobin and iron stores after appropriate recovery time.
8. Investigate nonresponse or recurrent deficiency rather than simply repeating infusions indefinitely.

Clinical Synopsis & Reasoning

Iron deficiency anemia is supported by low ferritin and transferrin saturation, but interpretation changes with inflammation because ferritin is an acute-phase reactant. Microcytosis and elevated red-cell distribution width can support the diagnosis but are not required. Before giving IV iron, determine why iron was lost or not absorbed. Menstrual blood loss, GI bleeding, pregnancy, bariatric surgery, inflammatory bowel disease, celiac disease, chronic kidney disease, and repeated phlebotomy are common contexts.

Oral iron remains appropriate for many stable patients, but IV iron is useful when oral therapy is not tolerated, absorption is impaired, ongoing losses exceed absorption, rapid repletion is clinically important, or prior oral therapy has failed. A patient with severe symptomatic anemia may also need red-cell transfusion depending on physiology, but transfusion and iron replacement solve different problems. Transfusion provides immediate oxygen-carrying capacity; it does not adequately replete depleted body iron stores.

Calculate the approximate iron deficit or use product-approved total replacement regimens. Modern formulations differ in how much elemental iron can be given per session. Ferric derisomaltose, ferric carboxymaltose, ferumoxytol, and low-molecular-weight iron dextran can often deliver large doses in one or two visits, while iron sucrose usually requires several smaller infusions. Product labeling and institutional protocols should control exact dosing.

Treatment Strategy & Disposition

Select the formulation according to total iron requirement, access to infusion visits, CKD or dialysis status, prior reactions, payer constraints, and adverse effects. Monitor the patient during administration and for a period afterward according to product guidance. True severe anaphylaxis to modern IV iron is rare, but infusion reactions occur and can include flushing, chest or back discomfort, dyspnea, or hypotension. Stop the infusion and assess severity rather than reflexively treating every transient reaction as IgE anaphylaxis.

Ferric carboxymaltose is associated with a comparatively higher risk of hypophosphatemia through FGF23-mediated renal phosphate wasting, especially after repeated courses. Check phosphate in patients with symptoms, repeated exposure, malnutrition, bone disease, or other risk factors. Low-molecular-weight iron dextran can provide a complete replacement dose in selected protocols but requires product-specific administration precautions. High-molecular-weight iron dextran is no longer used in the United States.

Recheck hemoglobin and iron indices after enough time has elapsed for erythropoiesis rather than immediately after infusion, when serum iron measures can be misleading. Continue investigating and treating the bleeding or malabsorptive source. If hemoglobin fails to rise despite documented iron repletion, reassess the diagnosis, ongoing blood loss, inflammation, renal disease, marrow disease, and other nutrient deficiencies.

Epidemiology / Risk Factors

• Iron deficiency is the most common nutrient deficiency contributing to anemia worldwide.
• Menstrual and gastrointestinal blood loss are major causes in adults.
• Malabsorption and inflammatory bowel disease frequently make IV therapy preferable.
• CKD and dialysis patients commonly receive IV iron because oral replacement is often insufficient.

Investigations

Selection Considerations

Pharmacology

Prognosis / Complications

• Reticulocyte response begins within days and hemoglobin generally rises over subsequent weeks when the diagnosis is correct.
• Symptoms such as fatigue and exertional intolerance improve as hemoglobin and stores recover.
• Recurrent deficiency is likely if ongoing blood loss remains untreated.
• Severe persistent hypophosphatemia can cause weakness, bone pain, and osteomalacia after repeated exposure.

Patient Education / Counseling

• Explain that IV iron replaces iron stores but does not stop the source of blood loss.
• Transient metallic taste, flushing, or infusion discomfort can occur and should be reported immediately.
• Seek urgent help for wheeze, facial swelling, fainting, or severe breathing difficulty during or after infusion.
• Patients receiving ferric carboxymaltose repeatedly should report new muscle weakness or bone pain.
• Follow-up blood tests are still required even after a full replacement infusion.

Notes

Modern IV iron products have improved the practicality of complete iron replacement. The key selection issue is often how much elemental iron can be safely delivered per visit, not whether one brand is universally superior.

ASH is developing formal iron-deficiency-anemia guidelines, so current practice still draws on product evidence, specialty guidance, and disease-specific recommendations. The durable treatment of iron deficiency remains source identification plus adequate replacement.

References

1. American Society of Hematology Iron Deficiency Resources — Link
2. ASH Iron Deficiency Initiative — Link